ERBB2 and melanoma: For instance, CAR NK cells have already been generated to recognize CD19+/CD20+ B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia [204,205], CD33+ acute myeloid leukemia [206], CD138+ multiple myeloma [207], CD5+ T cell lymphoma [208], GD2+ neuroblastoma [209], GPA7+ melanoma [210], EGFR+/HER-2+ glioblastoma [211], EpCAM+/HER-2+ breast [201], CD24+/HER-2+ ovarian [212] ROBO-1+ pancreatic [213] and MUC-1+ carcinomas, including colorectal cancer [214].